


RLY-2608

Cat. No.:	HY-153306		
CAS No.:	2733573-94-7		
Molecular Formula:	C ₂₉ H ₁₄ ClF ₅ N ₆ O ₂		
Molecular Weight:	608.91		
Target:	PI3K		
Pathway:	PI3K/Akt/mTOR		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



BIOLOGICAL ACTIVITY

Description

RLY-2608 is a first-in-class allosteric mutant-selective inhibitor of PI3Kα^[1].

REFERENCES

[1]. Andreas Varkaris, et al. Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Kα inhibitor that decouples anti-tumor activity from hyperinsulinemia. *Cancer Discov.* 2023 Nov 2.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA